Impact of the Amecian Stop Smoking Intervention Study on Cigarette consumption

Por Manley, M., Pierce, J., Gilpin, E., Rosbrook, B, Berry, C, Wun, M
Publicado em 1997

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial

Por Cella, D, Escudier, B, Rini, B, Chen, C, Bhattacharyya, H, Tarazi, J, Rosbrook, B, Kim, S, Motzer, R
Publicado em 2013

Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours

Por Hoh, C K, Burris, H A, Bendell, J C, Tarazi, J, Rosbrook, B, Kim, S, Infante, J R, Reid, T R
Publicado em 2014

CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone

Por Wasan, H S, Springett, G M, Chodkiewicz, C, Wong, R, Maurel, J, Barone, C, Rosbrook, B, Ricart, A D, Kim, S, Spano, J-P
Publicado em 2009

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours

Por Martin, L P, Kozloff, M F, Herbst, R S, Samuel, T A, Kim, S, Rosbrook, B, Tortorici, M, Chen, Y, Tarazi, J, Olszanski, A J, Rado, T, Starr, A, Cohen, R B
Publicado em 2012

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours

Por Kozloff, M F, Martin, L P, Krzakowski, M, Samuel, T A, Rado, T A, Arriola, E, De Castro Carpeño, J, Herbst, R S, Tarazi, J, Kim, S, Rosbrook, B, Tortorici, M, Olszanski, A J, Cohen, R B
Publicado em 2012

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

Por Escudier, B, Michaelson, M D, Motzer, R J, Hutson, T E, Clark, J I, Lim, H Y, Porfiri, E, Zalewski, P, Kannourakis, G, Staehler, M, Tarazi, J, Rosbrook, B, Cisar, L, Hariharan, S, Kim, S, Rini, B I
Publicado em 2014